Chronic hepatitis B virus (HBV) infection continues to pose a major global health threat. The virus evades immune responses and antiviral therapies due to the persistence of covalently closed circular ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

which is designed to potentially cure chronic hepatitis B virus (HBV) infection. Currently, it is estimated that 300 million people worldwide are afflicted with chronic hepatitis B. PBGENE-HBV is ...

Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only a small subset of patients. Current oral antiviral agents effectively suppress viral ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations ...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.

Analysts at William Blair have suggested that the market for an HBV cure could be around the same size as for hepatitis C virus, which peaked at around $10 billion a year, but was a short-lived ...

Chronic HBV infection is an incurable pathogen responsible ... for the first time—and therefore could represent a potential cure.” Additionally, CBL137 might prove similarly useful to target ...